Overview

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Status:
Completed

Trial end date:
2019-11-25

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.

Phase:

Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Aromatase Inhibitors
Estradiol
Fulvestrant